Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 17/20 | 0.60 |
| ▸ | ITGA2B | P08514 | 17/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.55 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.55 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5896939 | 0.90 | ITGB3 (0.60) | ITGB3ITGA2BKDM4EHSD17B10 | |
| SCHEMBL5682522 | 0.88 | ITGB3 (0.65) | ITGB3ITGA2BKDM4EHSD17B10 | |
| SCHEMBL26490133 | 0.82 | HRH3 (0.60) | ITGB3ITGA2BKDM4EHRH3 | |
| SCHEMBL5677017 | 0.78 | ITGB3 (0.49) | ITGB3ITGA2BKDM4EHRH3 | |
| SCHEMBL20266986 | 0.78 | HRH3 (0.52) | ITGB3ITGA2BKDM4EHRH3 | |
| SCHEMBL5677265 | 0.77 | ITGB3 (0.54) | ITGB3ITGA2BKDM4EHSD17B10 | |
| SCHEMBL5680312 | 0.77 | NHERF1 (0.54) | ITGB3ITGA2BKDM4EHSD17B10 | |
| SCHEMBL6809926 | 0.77 | HRH3 (0.51) | ITGB3ITGA2BKDM4EHRH3 | |
| SCHEMBL5889830 | 0.77 | KDM4E (0.57) | ITGB3ITGA2BKDM4EHSD17B10 | |
| SCHEMBL16492505 | 0.76 | HDAC3 (0.65) | ITGB3ITGA2BKDM4EHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7141680-B2 | Aromatic compounds possessing antifungal or antibacterial activity | GENELABS TECHNOLOGIES, INC. | 2006-11-28 | — | — | US | disclosed |
| US-20040063645-A1 | Novel aromatic compounds possessing antifungal or antibacterial activity | SMITHKLINE BEECHAM CORPORATION | 2004-04-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040063645-A1 | Novel aromatic compounds possessing antifungal or antibacterial activity | ZC3HAV1, TYR, ZC3HAV1L | ITGB3 4436/4885ITGA2B 4759/4885KDM4E 986/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.